APA (7th ed.) Citation

MS, B., JHA, C., J, M., S, P., DCA, Q., T, K., . . . A, H. (2025). The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: The phase 1a PROTA trial. Nature communications, 16(1), 1381. https://doi.org/10.1038/s41467-025-56482-w

Chicago Style (17th ed.) Citation

MS, Block, et al. "The Oncolytic Adenovirus TILT-123 with Pembrolizumab in Platinum Resistant or Refractory Ovarian Cancer: The Phase 1a PROTA Trial." Nature Communications 16, no. 1 (2025): 1381. https://doi.org/10.1038/s41467-025-56482-w.

MLA (9th ed.) Citation

MS, Block, et al. "The Oncolytic Adenovirus TILT-123 with Pembrolizumab in Platinum Resistant or Refractory Ovarian Cancer: The Phase 1a PROTA Trial." Nature Communications, vol. 16, no. 1, 2025, p. 1381, https://doi.org/10.1038/s41467-025-56482-w.